Denmark-based biotech Curasight making strides in cancer therapies

October 10, 2016 Christoph Graener

CSO and Co-Founder of Curasight Andreas Kjaer spoke with Informa Pharma Intelligence at BioPharm America about his company’s efforts to develop novel, innovative radionuclide therapies for cancer. With two completed Phase I trials and an ongoing Phase II study with its lead candidate in breast cancer, this Denmark-headquartered biotech also is developing companion diagnostic PET imaging ligands to improve diagnosis, treatment and outcomes in cancer. Krasilnikoff also talked about Curasight’s efforts to raise its profile in North America, including potential partnering talks at BioPharm America in Boston.

Interviewer: Joe Haas – Senior Writer, Scrip
Interviewee: Andreas Kjaer – CSO and Co-Founder, Curasight

Previous Article
Biotechs scramble as public markets dry up, but can private equity help?
Biotechs scramble as public markets dry up, but can private equity help?

Does the slump in the IPO boom create a bigger pool of private capital to invest in drug development, or do...

Next Article
CureDuchenne: The Mom Filter scores three profitable exits, one FDA approval
CureDuchenne: The Mom Filter scores three profitable exits, one FDA approval

Debra Miller takes drug development very seriously when it has anything to do with Duchenne muscular dystro...